Coya Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
COYA$3.16-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
CONDENSED BALANCE SHEETS
| (unaudited) | ||
|---|---|---|
| September 30, | December 31, | |
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $35,802,136 | $46,822,786 |
| Prepaids and other current assets | 3,268,059 | 3,116,232 |
| Total current assets | 39,070,195 | 49,939,018 |
| Fixed assets, net | 2,807 | 11,227 |
| Other assets | 244,727 | - |
| Total assets | $39,317,729 | $49,950,245 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,451,731 | $1,061,122 |
| Accrued expenses | 1,778,698 | 3,612,913 |
| Deferred collaboration revenue | 1,164,438 | 1,197,856 |
| Total current liabilities | 5,394,867 | 5,871,891 |
| Deferred collaboration revenue | 354,516 | 1,050,124 |
| Total liabilities | 5,749,383 | 6,922,015 |
| Commitments and contingencies (Note 6) | ||
| Stockholders' equity: | ||
| Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued or outstanding as of September 30, 2026 or December 31, 2025 | - | - |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 23,457,849 and 20,934,456 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 2,346 | 2,094 |
| Additional paid-in capital | 119,992,268 | 104,989,413 |
| Accumulated deficit | (86,426,268) | (61,963,277) |
| Total stockholders' equity | 33,568,346 | 43,028,230 |
| Total liabilities and stockholders' equity | $39,317,729 | $49,950,245 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.